| Code | CSB-RA004902MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to KH-801, targeting CD24, a small, heavily glycosylated cell surface protein anchored via glycosylphosphatidylinositol (GPI). CD24 functions as a co-stimulatory molecule in immune cell regulation and plays critical roles in cell adhesion, differentiation, and apoptosis. This protein is expressed on developing B cells, neutrophils, and various epithelial cells. CD24 has gained significant attention in oncology research due to its overexpression in multiple cancer types, including breast, ovarian, pancreatic, and lung cancers, where it correlates with tumor progression, metastasis, and poor prognosis. Additionally, CD24 serves as a cancer stem cell marker and contributes to immune evasion mechanisms in the tumor microenvironment.
KH-801 is a reference antibody utilized in cancer immunology research to investigate CD24-mediated signaling pathways and tumor biology. This biosimilar provides researchers with a reliable tool for studying CD24's role in cancer development, immune modulation, and potential therapeutic targeting strategies in oncological and immunological research contexts.
There are currently no reviews for this product.